Mylan gets FDA approval for generic Keppra

11/5/2008 | Boston Globe (tiered subscription model), The

Mylan secured FDA clearance to sell levetiracetam, a copy of UCB's epilepsy medicine Keppra. Mylan has begun shipments of the product, which are available in 250-mg, 500-mg and 750-mg tablets. UCB retains exclusive rights to market Keppra for pediatric use until it loses U.S. patent protection in January.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY